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Purpose of the study
Despite the introduction of HAART, Pneumocystis jirovecii
pneumonia (PCP) remains an important cause of mor-
bidity and mortality associated with HIV. This study
describes the treatment, mortality rate and predictors of
severity of PCP in the Glasgow HIV cohort since the intro-
duction of HAART.
Methods
A retrospective case review of all HIV-associated PCP epi-
sodes occurring between January 1997 and July 2008
within the greater Glasgow area was undertaken. Out-
come measures of severity were admission to the intensive
care or high dependency unit or death.
Summary of results
There were 69 episodes of PCP over the 11-year period.
The median age was 37 years, (range 15–66). The median
CD4 count was 30.5 (range 1–244). In 78% of cases PCP
was the presenting illness of HIV. Mortality was 8% by 28
days rising to 10% by 90 days. 16% of cases necessitated
admission to the high dependency or intensive care unit.
Multivariate analysis identified factors associated with
poor outcome as being a higher baseline urea (adjusted
odds ratio [AOR] 1.72; 95% CI 1.13–2.61; p = 0.011), a
higher white cell count (AOR 1.56; 95% CI 1.10–2.21; p
= 0.012 and a lower CD4 (AOR 0.93; 95%CI 0.87–0.99; p
= 0.05). Likelihood of admission to ITU or HDU was not
associated with prior cotrimoxazole prophylaxis, smok-
ing, any comorbidity, time since HIV diagnosis or SAPSII
score. 100% of those who did require admission to ITU or
HDU had a pO2 on admission of 8 or less on air com-
pared to only 54.14% of those who did not (p = 0.02)
74% of cases received high dose intravenous (IV) cotri-
moxazole as first-line therapy with 20% receiving oral cot-
rimoxazole from admission. There was no relationship
between admission SAPSII score, any admission blood
parameter or prior cotrimoxazole prohylaxis with the
decision to give oral or IV cotrimoxazole. 70% of cases
received corticosteroids. Multivariate analysis identified
factors associated with giving corticosteroids as being
prior cotrimoxazole prophylaxis (AOR 0.03; 95% CI
0.001–0.71; p = 0.029), lower pO2 breathing room air
(AOR 0.06; 95% CI 0.01–0.38; p = 0.003). Of those indi-
viduals antiretroviral naive, the median time from diagno-
sis of PCP to commencing ARV medication was 18 days
(95% CI 14.5–23.4).
Conclusion
The majority of cases of PCP occur in the context of a new
HIV diagnosis. Risk factors for poor outcome can be iden-
tified at admission and treatment decisions are influenced
by severity of illness and prior treatment.
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